{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:44:10Z","timestamp":1771040650860,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T00:00:00Z","timestamp":1618617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11864-021-00851-2","type":"journal-article","created":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T18:02:23Z","timestamp":1618682543000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["When to Stop TKIs in Patients with Chronic Myeloid Leukemia and How to Follow Them Subsequently"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-3840","authenticated-orcid":false,"given":"Nuno","family":"Cerveira","sequence":"first","affiliation":[]},{"given":"Susana","family":"Bizarro","sequence":"additional","affiliation":[]},{"given":"Manuel R.","family":"Teixeira","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 M.","family":"Mariz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,17]]},"reference":[{"issue":"10","key":"851_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96(10):3343\u201356.","journal-title":"Blood"},{"issue":"24","key":"851_CR2","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"851_CR3","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garc\u00eda-Guti\u00e9rrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30(8):1648\u201371.","journal-title":"Leukemia."},{"issue":"6","key":"851_CR4","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjh.15542","volume":"182","author":"NCP Cross","year":"2018","unstructured":"Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, et al. Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK. Br J Haematol. 2018;182(6):777\u201388.","journal-title":"Br J Haematol"},{"issue":"4","key":"851_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"\u2022\u2022 Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384 The 2020 update of the European Leukemia Net recommendations for the treatment, evaluation and follow-up of patients with CML.","journal-title":"Leukemia"},{"issue":"15","key":"851_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"851_CR7","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/s41375-018-0341-4","volume":"33","author":"M Baccarani","year":"2019","unstructured":"Baccarani M, Castagnetti F, Gugliotta G, Rosti G, Soverini S, Albeer A, et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia. 2019;33(5):1173\u201383.","journal-title":"Leukemia."},{"issue":"1","key":"851_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109(1):58\u201360.","journal-title":"Blood."},{"issue":"11","key":"851_CR9","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"\u2022\u2022 Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335 The first prospective trial for discontinuation TKI treatment which showed that 38% of selected CML patients could maintain a sustained molecular remission after treatment interruption.","journal-title":"Lancet Oncol"},{"issue":"35","key":"851_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","volume":"20","author":"G Etienne","year":"2017","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;20(35):298\u2013305.","journal-title":"J Clin Oncol"},{"issue":"4","key":"851_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515\u201322.","journal-title":"Blood."},{"issue":"12","key":"851_CR12","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","volume":"32","author":"DM Ross","year":"2018","unstructured":"Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018;32(12):2572\u20139.","journal-title":"Leukemia."},{"issue":"22","key":"851_CR13","doi-asserted-by":"publisher","first-page":"6606","DOI":"10.1158\/1078-0432.CCR-18-3373","volume":"25","author":"FE Nicolini","year":"2019","unstructured":"Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, et al. Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients. Clin Cancer Res. 2019;25(22):6606\u201313.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"851_CR14","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10147-018-1368-2","volume":"24","author":"S Fujisawa","year":"2019","unstructured":"Fujisawa S, Ueda Y, Usuki K, Kobayashi H, Kondo E, Doki N, et al. Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial). Int J Clin Oncol. 2019;24(4):445\u201353.","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"851_CR15","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"\u2022 Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424\u201330 A multicenter observational study that showed that loss of MMR was a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR.","journal-title":"J Clin Oncol"},{"issue":"6","key":"851_CR16","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3324\/haematol.2015.139899","volume":"101","author":"SE Lee","year":"2016","unstructured":"Lee SE, Choi SY, Song HY, Kim SH, Choi MY, Park JS, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica. 2016;101(6):717\u201323.","journal-title":"Haematologica."},{"issue":"10","key":"851_CR17","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/ajh.24120","volume":"90","author":"S Mori","year":"2015","unstructured":"Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910\u20134.","journal-title":"Am J Hematol"},{"issue":"2","key":"851_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s12185-017-2334-x","volume":"107","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study. Int J Hematol. 2018;107(2):185\u201393.","journal-title":"Int J Hematol"},{"issue":"6","key":"851_CR19","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","volume":"19","author":"S Saussele","year":"2018","unstructured":"\u2022\u2022 Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747\u201357 The largest clinical trial of TKI discontinuation in patients with CML that confirmed that patients with CML who have achieved deep molecular responses have good molecular relapse-free survival, particularly those who have been in deep molecular response for a long time.","journal-title":"Lancet Oncol"},{"issue":"7","key":"851_CR20","doi-asserted-by":"publisher","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","volume":"4","author":"RE Clark","year":"2017","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol. 2017;4(7):e310\u2013e16.","journal-title":"Lancet Haematol"},{"issue":"7","key":"851_CR21","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375\u2013e83.","journal-title":"Lancet Haematol"},{"issue":"3","key":"851_CR22","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2352-3026(19)30235-2","volume":"7","author":"S Kimura","year":"2020","unstructured":"Kimura S, Imagawa J, Murai K, Hino M, Kitawaki T, Okada M, et al. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2020;7(3):e218\u2013e25.","journal-title":"Lancet Haematol"},{"issue":"12","key":"851_CR23","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol. 2015;2(12):e528\u201335.","journal-title":"Lancet Haematol"},{"issue":"5","key":"851_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clml.2018.03.004","volume":"18","author":"M Okada","year":"2018","unstructured":"Okada M, Imagawa J, Tanaka H, Nakamae H, Hino M, Murai K, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second- line treatment. Clin Lymphoma Myeloma Leuk. 2018;18(5):353\u201360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"851_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/cas.13430","volume":"109","author":"T Kumagai","year":"2018","unstructured":"Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, et al. Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation. Cancer Sci. 2018;109(1):182\u201392.","journal-title":"Cancer Sci"},{"issue":"3","key":"851_CR26","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","volume":"61","author":"NP Shah","year":"2020","unstructured":"Shah NP, Garc\u00eda-Guti\u00e9rrez V, Jim\u00e9nez-Velasco A, Larson S, Saussele S, Rea D, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650\u20139.","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"851_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","volume":"129","author":"D Rea","year":"2017","unstructured":"Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood. 2017;129(7):846\u201354.","journal-title":"Blood."},{"issue":"11","key":"851_CR28","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3324\/haematol.2018.194894","volume":"103","author":"N Takahashi","year":"2018","unstructured":"Takahashi N, Nishiwaki K, Nakaseko C, Aotsuka N, Sano K, Ohwada C, et al. Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. Haematologica. 2018;103(11):1835\u201318.","journal-title":"Haematologica."},{"issue":"7","key":"851_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/M17-1094","volume":"168","author":"FX Mahon","year":"2018","unstructured":"Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, et al. Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study. Ann Intern Med. 2018;168(7):461\u201370.","journal-title":"Ann Intern Med"},{"issue":"7","key":"851_CR30","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525\u201331.","journal-title":"Leukemia."},{"issue":"5","key":"851_CR31","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","volume":"144","author":"DM Ross","year":"2018","unstructured":"Ross DM, Masszi T, G\u00f3mez Casares MT, Hellmann A, Stentoft J, Conneally E, et al. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study. J Cancer Res Clin Oncol. 2018;144(5):945\u201354.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"851_CR32","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/bjh.16408","volume":"189","author":"S Dulucq","year":"2020","unstructured":"Dulucq S, Astrugue C, Etienne G, Mahon FX, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020;189(3):452\u201368.","journal-title":"Br J Haematol"},{"key":"851_CR33","doi-asserted-by":"crossref","unstructured":"Benjamini O, Kantarjian H, Rios MB, Jabbour E, O\u2019Brien S, Jain P, et al. Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience. Leuk Lymphoma. 2014 Dec;55(12):2879\u201386.","DOI":"10.3109\/10428194.2013.831092"},{"issue":"1","key":"851_CR34","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1186\/s12885-018-5167-y","volume":"18","author":"N Cerveira","year":"2018","unstructured":"Cerveira N, Loureiro B, Bizarro S, Correia C, Torres L, Lisboa S, et al. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution. BMC Cancer. 2018;18(1):1245.","journal-title":"BMC Cancer"},{"issue":"7","key":"851_CR35","doi-asserted-by":"publisher","first-page":"e375","DOI":"10.1016\/S2352-3026(19)30094-8","volume":"6","author":"RE Clark","year":"2019","unstructured":"Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, et al. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet Haematol. 2019;6(7):e375\u2013e83.","journal-title":"Lancet Haematol"},{"issue":"8","key":"851_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41571-020-0367-1","volume":"17","author":"DM Ross","year":"2020","unstructured":"Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nat Rev Clin Oncol. 2020;17(8):493\u2013503.","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"851_CR37","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1111\/bjh.16058","volume":"186","author":"N Cerveira","year":"2019","unstructured":"Cerveira N, Diamond J, Matos S, Amorim ML, Coucelo M, Bizarro S, et al. Negative MR4\u00b70 chronic myeloid leukaemia and its possible implications for treatment-free remission. Br J Haematol. 2019;186(6):e181\u2013e4.","journal-title":"Br J Haematol"},{"issue":"5","key":"851_CR38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","volume":"32","author":"P Rousselot","year":"2014","unstructured":"Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32(5):424\u201330.","journal-title":"J Clin Oncol"},{"issue":"7-8","key":"851_CR39","doi-asserted-by":"publisher","first-page":"550","DOI":"10.20344\/amp.11823","volume":"32","author":"A Almeida","year":"2019","unstructured":"Almeida A, Pierdomenico F, Guerrero BP, Saraiva S, Montalv\u00e3o A, Coutinho J, et al. Recommendations from a Portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice. Acta Medica Port. 2019;32(7-8):550\u20137.","journal-title":"Acta Medica Port"},{"key":"851_CR40","unstructured":"National Comprehensive Cancer Network (2018) Chronic Myeloid Leukemia (Version 2.2021). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cml.pdf. Accessed 2021-04-02."},{"issue":"22","key":"851_CR41","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1002\/cncr.30885","volume":"123","author":"L Legros","year":"2017","unstructured":"Legros L, Nicolini FE, Etienne G, Rousselot P, Rea D, Giraudier S, et al. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia. Cancer. 2017;123(22):4403\u201310.","journal-title":"Cancer."},{"issue":"12","key":"851_CR42","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","volume":"32","author":"DM Ross","year":"2018","unstructured":"Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. 2018;32(12):2572\u20139.","journal-title":"Leukemia."},{"issue":"12","key":"851_CR43","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot P, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505\u20138.","journal-title":"Blood."},{"issue":"12","key":"851_CR44","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111\u20135.","journal-title":"Am J Hematol"},{"issue":"1","key":"851_CR45","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.18.00814","volume":"37","author":"N Cerveira","year":"2019","unstructured":"Cerveira N, Almeida A. Evidence-based criteria for tyrosine kinase inhibitor interruption in pregnancy. J Clin Oncol. 2019;37(1):89\u201390.","journal-title":"J Clin Oncol"},{"issue":"7","key":"851_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/leu.2017.63","volume":"31","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, G\u00f3mez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31(7):1525\u201331.","journal-title":"Leukemia."},{"issue":"6","key":"851_CR47","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1097\/HS9.0000000000000157","volume":"2","author":"A Papalexandri","year":"2018","unstructured":"Papalexandri A, Saloum R, Touloumenidou T, Papathanasiou M, Lalayanni C, Baldoumi E, et al. Blast crisis of CML after TKI discontinuation in a patient with previous stable deep molecular response: is it safe to stop? Hemasphere. 2018;2(6):e157.","journal-title":"Hemasphere"},{"key":"851_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2019-124408","volume":"134","author":"R Rea","year":"2019","unstructured":"Rea R, Nicolini FE, Tulliez M, Rousselot P, Gardembas M, Etienne G, et al. Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): A FI-LMC STOP 2G-TKI Study Update. Blood. 2019;134:30.","journal-title":"Blood"},{"key":"851_CR49","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","volume":"32","author":"J Richter","year":"2014","unstructured":"Richter J, Soderlund S, Lubking A, Dreimane A, Lotfi K, Markevarn B, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32:2821\u20133.","journal-title":"J Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00851-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-021-00851-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-021-00851-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,9]],"date-time":"2021-06-09T14:27:55Z","timestamp":1623248875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-021-00851-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,17]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["851"],"URL":"https:\/\/doi.org\/10.1007\/s11864-021-00851-2","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,17]]},"assertion":[{"value":"16 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nuno Cerveira declares that he has no conflict of interest. Susana Bizarro declares that she has no conflict of interest. Manuel R. Teixeira declares that he has no conflict of interest. Jos\u00e9 M. Mariz declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"49"}}